For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Corcept Therapeutics Inc (NASDAQ: CORT) closed at $76.65 up 7.81% from its previous closing price of $71.1. In other words, the price has increased by $7.81 from its previous closing price. On the day, 1.02 million shares were traded. CORT stock price reached its highest trading level at $77.01 during the session, while it also had its lowest trading level at $67.0.
Ratios:
For a deeper understanding of Corcept Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 46.00. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 03 ’25 when Lyon Joseph Douglas sold 5,000 shares for $73.65 per share. The transaction valued at 368,244 led to the insider holds 10,277 shares of the business.
BELANOFF JOSEPH K sold 28,782 shares of CORT for $2,152,105 on Nov 05 ’25. The Chief Executive Officer now owns 2,741,370 shares after completing the transaction at $74.77 per share. On Nov 03 ’25, another insider, BELANOFF JOSEPH K, who serves as the Chief Executive Officer of the company, sold 11,218 shares for $74.08 each. As a result, the insider received 831,014 and left with 2,770,152 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 8062676992 and an Enterprise Value of 7156308992. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 87.58, and their Forward P/E ratio for the next fiscal year is 44.43. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.09 while its Price-to-Book (P/B) ratio in mrq is 12.75. Its current Enterprise Value per Revenue stands at 9.994 whereas that against EBITDA is 69.735.
Stock Price History:
The Beta on a monthly basis for CORT is 0.21, which has changed by 0.3093922 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $49.00. The 50-Day Moving Average of the stock is -0.03%, while the 200-Day Moving Average is calculated to be 8.19%.
Shares Statistics:
For the past three months, CORT has traded an average of 830.94K shares per day and 665870 over the past ten days. A total of 105.12M shares are outstanding, with a floating share count of 93.32M. Insiders hold about 11.43% of the company’s shares, while institutions hold 76.04% stake in the company. Shares short for CORT as of 1760486400 were 10239885 with a Short Ratio of 12.32, compared to 1757894400 on 10805275. Therefore, it implies a Short% of Shares Outstanding of 10239885 and a Short% of Float of 13.13.
Earnings Estimates
A comprehensive evaluation of Corcept Therapeutics Inc (CORT) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.81 and $0.81 for the fiscal current year, implying an average EPS of $0.81. EPS for the following year is $0.78, with 1.0 analysts recommending between $0.78 and $0.78.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $260.57M this quarter.It ranges from a high estimate of $272.4M to a low estimate of $248.59M. As of. The current estimate, Corcept Therapeutics Inc’s year-ago sales were $181.89MFor the next quarter, 3 analysts are estimating revenue of $260M. There is a high estimate of $300M for the next quarter, whereas the lowest estimate is $220M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $831.7M, while the lowest revenue estimate was $807.9M, resulting in an average revenue estimate of $819.25M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.15B in the next fiscal year. The high estimate is $1.39B and the low estimate is $1.01B.
